- Home
- SAN vs BMY Comparison
SAN vs BMY Comparison
Compare SAN & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAN | BMY |
|---|---|---|
| Founded | 1857 | 1887 |
| Country | Spain | United States |
| Employees | 204330 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.1B | 95.0B |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | SAN | BMY |
|---|---|---|
| Price | $11.34 | $52.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $55.92 |
| AVG Volume (30 Days) | 2.9M | ★ 15.2M |
| Earning Date | 10-29-2025 | 10-30-2025 |
| Dividend Yield | 1.63% | ★ 4.73% |
| EPS Growth | ★ 14.58 | N/A |
| EPS | 1.00 | ★ 2.97 |
| Revenue | ★ $59,455,590,761.00 | $48,034,000,000.00 |
| Revenue This Year | $23.33 | $0.23 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $11.34 | $17.64 |
| Revenue Growth | ★ 8.72 | 1.26 |
| 52 Week Low | $4.43 | $42.52 |
| 52 Week High | $11.57 | $63.33 |
Technical Indicators
Market Signals| Indicator | SAN | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 66.78 | 68.42 |
| Support Level | $10.92 | $50.33 |
| Resistance Level | $11.59 | $52.51 |
| Average True Range (ATR) | 0.16 | 1.12 |
| MACD | 0.06 | 0.18 |
| Stochastic Oscillator | 83.89 | 89.75 |
Price Performance
Historical ComparisonAbout SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.